<div id="readability-page-1">DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) told shareholders it is entering 2026 with advancing cancer programs, improving clinical signals, and a cash runway that management says extends into …</div>

APRE

<p>宾夕法尼亚州道尔斯敦 — Aprea Therapeutics, Inc.（纳斯达克：APRE）告诉股东，公司将在 2026 年进入时，癌症项目正在推进，临床信号改善，管理层表示现金流将持续到……</p>

Aprea 表示，随着癌症试验的进展和资金的延续，2026 年将迎来一个转折点